Moreover, the antiproliferative RNR inhibitor MB and the proapoptotic Bcl-2 inhibitor ABT-737 generate a synergistic therapeutic effect on AML cells, suggesting that rational combination treatment may also exert synergistic effects on other malignancies. Here, NR2E3 is linked to acute myeloid leukemia.